Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 6Mycosis Fungoides 5Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Stomach Neoplasms 1Solid Tumor 1Recurrence 1Mouth Neoplasms 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, T-Cell 1Kidney Neoplasms 1Esophageal Neoplasms 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 5pegaspargase 3Vincristine 3Methotrexate 3Mercaptopurine 3Etoposide 3Dexamethasone 3Cytarabine 3fludarabine 2Radiotherapy 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Karyotyping 2Injections, Spinal 2Idarubicin 2Doxorubicin 2nelarabine 1mogamulizumab 1Positron Emission Tomography Computed Tomography 1Panobinostat 1Mitoxantrone 1Melphalan 1Everolimus 1Clofarabine 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, T-Cell × mogamulizumab × Clear all
NCT06698003 2026-03-05

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
134 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡